Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has become a standard first-line treatment for patients with metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations (Isobe et al., 2021). Here, EGFR is linked to non-small cell lung carcinoma.